<DOC>
	<DOCNO>NCT01233882</DOCNO>
	<brief_summary>This two-staged study single dose 200 mg bosutinib give subject renal impairment match healthy volunteer . In Stage 1 , subject severe renal impairment subject normal renal function enrol . Subjects mild moderate renal impairment enrol Stage 2 result Stage 1 suggest substantial difference PK profile subject severe renal impairment subject normal renal function .</brief_summary>
	<brief_title>Bosutinib In Subjects With Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Males female , age 18 65 . Adequate hepatic function . Documented creatinine clearance CockroftGault formula indicative respective level renal impairment : Severe renal impairment ( CrCl &lt; 30 mL/min/1.73m2 ) , moderate renal impairment ( 30 ≤ CrCl ≤50 mL/min/1.73m2 ) , mild renal impairment ( 50 &lt; CrCl≤80 mL/min/1.73m2 ) normal renal function ( CrCl &gt; 80 mL/min/1.73m2 ) . Use investigational drug biologic within 4 week prior screen visit screen period . Ongoing treatment Digoxin strong CYP3A4 inhibitor inducer . Uncontrolled hypertension ( renally impair subject ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Renal impairment</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>